Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases
From MaRDI portal
Publication:326548
Abstract: While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell populations that harbor pre-existing resistance to the drug, and those that acquire resistance during the course of treatment. For each of these independent scenarios, we consider one hypothetical cell line that is responsive to metronomic chemotherapy, and another that with high probability cannot be eradicated by a metronomic protocol. Motivated by experimental work on ovarian cancer xenografts, we consider all possible combinations of a one week treatment protocol, repeated for three weeks, and constrained by the total weekly drug dose. Simulations reveal a small number of fractionated-dose protocols that are at least as effective as metronomic therapy in eradicating micrometastases with acquired resistance (weak or strong), while also being at least as effective on those that harbor weakly pre-existing resistant cells. Given the responsiveness of very different theoretical cell lines to these few fractionated-dose protocols, these may represent more effective ways to schedule chemotherapy with the goal of limiting metastatic tumor progression.
Recommendations
- Emergence of anti-cancer drug resistance: exploring the importance of the microenvironmental niche via a spatial model
- Modeling the impact of anticancer agents on metastatic spreading
- Global analysis of a cancer model with drug resistance due to microvesicle transfer
- A stochastic model for the origin and treatment of tumors containing drug-resistant cells
- A mathematical model of drug resistance: Heterogeneous tumors
- Global analysis of a cancer model with drug resistance due to Lamarckian induction and microvesicle transfer
- Modeling the transfer of drug resistance in solid tumors
- An elementary approach to modeling drug resistance in cancer
- An elementary mathematical modeling of drug resistance in cancer
- A Mathematical Model of a Micrometastasis
Cites Work
- A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy
- A stochastic model for the origin and treatment of tumors containing drug-resistant cells
- Drug resistance in cancer chemotherapy as an optimal control problem
- Dynamics and control of a mathematical model for metronomic chemotherapy
- Emergence of anti-cancer drug resistance: exploring the importance of the microenvironmental niche via a spatial model
- Evolution of resistance to anti-cancer therapy during general dosing schedules
- Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
- Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors
- On the MTD paradigm and optimal control for multi-drug cancer chemotherapy
- Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies
- Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer
- The impact of cell density and mutations in a model of multidrug resistance in solid tumors
Cited In (4)
- Including blood vasculature into a game-theoretic model of cancer dynamics
- Emergence of anti-cancer drug resistance: exploring the importance of the microenvironmental niche via a spatial model
- Comparison of drug inhibitory effects \((\mathrm{IC}_{50})\) in monolayer and spheroid cultures
- Do mechanisms matter? Comparing cancer treatment strategies across mathematical models and outcome objectives
This page was built for publication: Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q326548)